Immunoprecise Antibodies Ltd - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
IPA New York 2836 https://immunoprecise.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Immunoprecise Antibodies Ltd

IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2023 - Mar 16th, 2023 12:04 pm
ImmunoPrecise Antibodies’ Subsidiary Talem Therapeutics Announces a Multi-Target AI-Driven Antibody Discovery Collaboration with Libera Bio - Mar 15th, 2023 12:04 pm
IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2023 on March 16, 2023 - Mar 7th, 2023 1:52 pm
IPA Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2023 - Dec 15th, 2022 1:04 pm
IPA’s Subsidiary BioStrand Completes Integration of 20 Million Proprietary Structural HYFTs™ and Accelerates in Silico Drug Discovery Developments - Dec 8th, 2022 1:04 pm
IPA to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2023 on December 15, 2022 - Dec 5th, 2022 1:04 pm
IPA’s Subsidiary BioStrand and BriaCell Announce Artificial Intelligence Collaboration and License Agreement to Discover and Develop Anti-Cancer Antibodies - Nov 30th, 2022 1:04 pm
ImmunoPrecise Antibodies Ltd. Announces Voluntary Delisting from TSX Venture Exchange - Nov 22nd, 2022 1:04 pm
IPA’s Subsidiary Talem Therapeutics Licenses Antibodies for Three OmniChicken-Derived Programs - Oct 12th, 2022 12:04 pm
NIAID Confirms IPA’s PolyTope TATX-03 Neutralizing Activity Against the Currently Spreading SARS-CoV-2 Variant BA.2.75 - Sep 14th, 2022 12:31 pm
IPA Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2023 - Sep 14th, 2022 12:04 pm
IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2023 on September 14, 2022 - Sep 8th, 2022 1:03 pm
Live Virus Assays at Ludwig-Maximilians-Universität München Confirm PolyTope’s Efficacy Against SARS-CoV-2 Variants Including BA.5 - Aug 29th, 2022 12:04 pm
ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2022 - Jul 29th, 2022 12:04 pm
IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2022 on July 29, 2022 - Jul 26th, 2022 12:04 pm
Histopathology Data of Preclinical Repeated Dose Toxicity Study and ex vivo Human Tissue Cross-Reactivity (TCR) Analysis Support Safety of IPA’s PolyTope® TATX-03, a Synergistic Antibody Cocktail against SARS‑CoV‑2 - Jul 12th, 2022 12:04 pm
Despite currently being unprofitable, ImmunoPrecise Antibodies (CVE:IPA) has delivered a 44% return to shareholders over 3 years - Jun 25th, 2022 2:52 pm
IPA’s Subsidiary BioStrand Secures Second VLAIO Research Grant - May 9th, 2022 12:03 pm
IPA’s Advanced PolyTope® TATX-03, a Multi-Antibody Cocktail, Potently Prevents In Vitro Infection of Cells by the Currently Dominant Omicron Sublineage BA.2, in Addition to all Other Variants of Concern - Apr 20th, 2022 12:01 pm
IPA Completes Acquisition of Belgian Technology Companies BioStrand, BioKey, and BioClue – Adding Artificial Intelligence-Driven Analytics to its Antibody Discovery Capabilities and Offerings - Apr 14th, 2022 12:01 pm